Clinical bottom line
Modulation of the gut microbiome represents a promising avenue to influence immune responses in autoimmune diseases. Emerging evidence suggests that targeted interventions on gut microbial composition and function can attenuate disease activity and may complement existing therapies. However, clinical application remains in early stages, with mechanistic insights largely derived from preclinical and observational studies. Further rigorous trials are needed to validate efficacy, optimize interventions, and clarify long-term safety.
What the evidence shows
The gut microbiome plays a pivotal role in shaping systemic immune responses, with dysbiosis implicated in the pathogenesis of various autoimmune diseases (Miyauchi et al., 2023). Alterations in microbial diversity and function can disrupt intestinal barrier integrity and modulate mucosal immunity, thereby influencing extra-intestinal autoimmunity.
In rheumatoid arthritis (RA), Zhao et al. (2022) detail how specific microbial taxa contribute to disease onset and progression by promoting pro-inflammatory pathways. Therapeutic strategies targeting the microbiome—such as probiotics, prebiotics, dietary modification, and fecal microbiota transplantation—have shown potential to restore immune homeostasis and reduce inflammation.
Zhang et al. (2025) demonstrated that targeted modulation of the intestinal barrier and mucosal immune-related microbiota attenuated progression of IgA nephropathy, an autoimmune kidney disease, highlighting the translational potential of microbiome interventions beyond classical autoimmune disorders.
The gut microbiome–helminth–immune axis is another emerging area of interest. Shimokawa et al. (2025) reviewed how helminth-induced microbiome changes can exert immunoregulatory effects, suggesting that controlled helminth exposure or helminth-derived products might modulate autoimmune disease activity.
Dietary factors profoundly influence gut microbial composition and function, impacting autoimmune disease risk and activity (Mackay et al., 2020). Nutritional interventions tailored to optimize the microbiome may represent a non-pharmacologic adjunct in disease management.
Caveats and uncertainty
Most evidence is derived from animal models, small human cohorts, or observational studies, limiting causal inference and generalizability.
Heterogeneity in microbiome composition across individuals, influenced by genetics, environment, diet, and medications, complicates standardization of interventions.
Optimal microbiome targets, timing, and modalities of modulation remain undefined.
Long-term safety and unintended consequences of microbiome manipulation, including infection risk or dysbiosis-related complications, require careful evaluation.
Current clinical data on microbiome-based therapies in autoimmune diseases are sparse and often lack robust controls.
How this may change practice
Clinicians should recognize the gut microbiome as a modifiable factor influencing autoimmune disease pathogenesis and progression.
Incorporation of dietary counseling aimed at promoting microbiome health may complement standard immunotherapies.
Microbiome-targeted therapies, including probiotics or prebiotics, may be considered experimentally or in clinical trials, particularly for refractory cases.
Future integration of microbiome profiling could enable personalized therapeutic strategies.
Ongoing research may lead to novel microbiome-based diagnostics and therapeutics, expanding the armamentarium against autoimmune diseases.